Yale Center for Outcomes Research and Evaluation (CORE)
Harlan Krumholz is a cardiologist and the Harold H. Hines, Jr. Professor of Medicine, and the founder and Director of the Yale Center for Outcomes Research and Evaluation (CORE). He is a leading outcomes researcher and has published >1500 scientific articles, has an h-index >220 and is one of the most highly cited medical researchers. Dr. Krumholz pioneered strategies to measure and improve healthcare quality, outcomes, and health equity; promote open science and transform research processes; support patient empowerment; and apply digital technologies and computational approaches to accelerate progress in clinical care and research. He is a Distinguished Scientist of the American Heart Association and a member of the National Academy of Medicine, served as a member of the Advisory Committee to the Director of the National Institutes of Health, and was a founding Governor of the Patient-Centered Outcomes Research Institute (PCORI). Dr. Krumholz co-founded the Yale University Open Data Access (YODA) Project, Hugo Health (patient-centric platform to enable a consumer-mediated health information exchange), Refactor Health, (healthcare AI-augmented data insight company), ENSIGHT-AI (an AI-based diagnostic company) and medRxiv (non-profit preprint server for the medical and health sciences). For building transformative research platforms in China, he was awarded the Chinese Government’s Friendship Award, the highest award for foreign experts. He was the founding Editor of Circulation: Cardiovascular Quality and Outcomes and is the Editor-in-Chief of JACC. He grew up in Dayton, Ohio, and graduated from Yale College, Harvard Medical School, and the Harvard School of Public Health.
Disclosure(s): Element Science: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Ensight AI: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); F-Prime: Consultant/Advisory Board (Ongoing); Hugo Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Identifeye: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Janssen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Kenvue: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Refactor Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Various honoraria and/or travel expense payments for education presentations at academic and other venues: Speaker/Honoraria (Ongoing)
262 - JACC : VISIONS AND MISSION
Friday, October 25, 2024
4:50 PM – 5:10 PM PT